August 5, 2013

Sanofi Pasteur Initiates Phase III Study of Investigational Clostridium Difficile Vaccine

Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide

 

Sanofi Pasteur Initiates Phase III Study of Investigational Clostridium Difficile Vaccine
Cdiffense trial to evaluate vaccine against a leading cause of life-threatening, healthcare-associated infections worldwide

Lyon, France – August 5, 2013 – Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program called Cdiffense to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI). Clostridium difficile (C. diff) is a potentially life-threatening, spore-forming bacterium that causes intestinal disease. The risk of C. diff increases with age, antibiotic treatment and time spent in hospitals or nursing homes, where multiple cases can lead to outbreaks. The investigational vaccine is designed to help protect at-risk individuals from C. diff, which is emerging as a leading cause of life-threatening, healthcare- associated infections (HAIs) worldwide.